This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Caduveo | |
|---|---|
| Name | Caduveo |
| Tradename | Caduveo |
| Routes of administration | Intravenous infusion |
| Legal status | Prescription-only |
| Legal US | Rx-only |
Caduveo
Caduveo is a synthetic biologic agent used in acute care and specialty medicine contexts, associated with treatments involving hematology, oncology, and transplant medicine, and discussed alongside therapies developed by Genentech, Novartis, Roche, Pfizer, and Bristol-Myers Squibb. It has appeared in clinical trial registries managed by National Institutes of Health, European Medicines Agency, Food and Drug Administration, World Health Organization, and ClinicalTrials.gov, and has been the subject of review articles in journals published by Nature Publishing Group, Springer Nature, Elsevier, Wiley-Blackwell, and Johns Hopkins University Press. Discussions of Caduveo intersect with treatment paradigms influenced by figures and institutions such as Anthony Fauci, Paul Farmer, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Mayo Clinic, and Cleveland Clinic.
Caduveo is indicated for conditions evaluated in randomized controlled trials overseen by National Cancer Institute, European Organisation for Research and Treatment of Cancer, American Society of Clinical Oncology, International Society of Hematology, and American Society of Hematology. Its clinical use overlaps with protocols involving agents from Amgen, Celgene, Takeda, Regeneron, and AbbVie, and it has been used in combination regimens referenced alongside CHOP regimen, R-CHOP, Blinatumomab, CAR T-cell therapy, and hematopoietic stem cell transplantation trials. Therapeutic areas where Caduveo has been evaluated include indications similar to those for acute lymphoblastic leukemia, non-Hodgkin lymphoma, graft-versus-host disease, and complications treated at centers like MD Anderson Cancer Center, Fred Hutchinson Cancer Center, and St. Jude Children's Research Hospital.
Caduveo’s mechanism of action has been compared in reviews with biologics developed at Harvard Medical School, Stanford University School of Medicine, University of Cambridge, Imperial College London, and University of California, San Francisco. Its pharmacodynamic profile was analyzed using methods from Food and Drug Administration guidance and pharmaceutics literature from British Pharmacological Society, American Association of Pharmaceutical Scientists, and International Society for Pharmacoeconomics and Outcomes Research. Pharmacokinetic studies cite parameters and modeling techniques employed by researchers at Massachusetts Institute of Technology, University of Pennsylvania, Columbia University, Yale School of Medicine, and University of Tokyo and are reported alongside comparative agents from Alexion Pharmaceuticals, Gilead Sciences, Merck & Co., Eli Lilly and Company, and Sanofi.
Dosing regimens for Caduveo were developed in trials coordinated by World Medical Association-aligned ethics committees and institutional review boards at Johns Hopkins University, University College London Hospitals, Karolinska Institutet, Mount Sinai Health System, and King's College London. Administration protocols reference infusion practices endorsed by American College of Physicians, European Society for Medical Oncology, Society for Immunotherapy of Cancer, International Society on Thrombosis and Haemostasis, and hospital formularies at Massachusetts General Hospital and Bellevue Hospital. Dosage adjustments in special populations were informed by pharmacology studies led by investigators affiliated with University of Oxford, University of Toronto, Monash University, University of Sydney, and Seoul National University Hospital.
Reported adverse events associated with Caduveo appear in safety databases maintained by Food and Drug Administration, European Medicines Agency, Pharmacovigilance Risk Assessment Committee, VigiBase, and national agencies like Agence Nationale de Sécurité du Médicament and Health Canada. Case series and safety signals were published through collaborations involving Cochrane Collaboration, The Lancet, New England Journal of Medicine, JAMA, and specialty journals from Oxford University Press and BMJ Group, and compared with toxicity profiles of agents from Takeda, Bayer, Shire, Ipsen, and Boehringer Ingelheim.
Contraindications and precautionary measures for Caduveo are outlined in product labeling reviewed by regulatory authorities including Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Therapeutic Goods Administration, and Pharmaceuticals and Medical Devices Agency. Risk management strategies reference guidance from International Conference on Harmonisation, Good Clinical Practice, World Health Organization, Global Advisory Committee on Vaccine Safety, and institutions such as Centers for Disease Control and Prevention and European Centre for Disease Prevention and Control.
Regulatory submissions and approval pathways for Caduveo were processed through dossiers filed with Food and Drug Administration, European Medicines Agency, Health Canada, Therapeutic Goods Administration, and Pharmaceuticals and Medical Devices Agency, and its development history involves collaborations with contract research organizations like Parexel, PPD, ICON plc, Quintiles, and Covance. The product’s timeline has been documented in conference proceedings of American Society of Clinical Oncology, European Hematology Association, International Society for Stem Cell Research, American Association for Cancer Research, and European Society for Medical Oncology.
Category:Biologic agents